4//SEC Filing
TANG CAPITAL PARTNERS LP 4
Accession 0001209191-21-067347
CIK 0000920465other
Filed
Nov 30, 7:00 PM ET
Accepted
Dec 1, 7:07 PM ET
Size
18.3 KB
Accession
0001209191-21-067347
Insider Transaction Report
Form 4
TANG KEVIN C
Director10% Owner
Transactions
- Sale
Common Stock
2021-12-01$3.76/sh−136,255$512,128→ 9,649,224 total(indirect: By LP) - Sale
Common Stock
2021-11-30$3.95/sh−63,745$251,544→ 9,785,479 total(indirect: By LP) - Sale
Common Stock
2021-11-29$4.10/sh−193,403$793,107→ 9,855,821 total(indirect: By LP) - Sale
Common Stock
2021-11-30$3.95/sh−6,597$26,067→ 9,849,224 total(indirect: By LP) - Sale
Common Stock
2021-12-01$3.66/sh−41,290$151,303→ 9,607,934 total(indirect: By LP)
Footnotes (7)
- [F1]The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $4,380.25.
- [F2]The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.90 to $4.74. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 and 4 through 7 herein.
- [F3]The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP.
- [F4]The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.95 to $3.96.
- [F5]The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.90 to $4.051.
- [F6]The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.89.
- [F7]The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.60 to $3.75
Documents
Issuer
LA JOLLA PHARMACEUTICAL CO
CIK 0000920465
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001191935
Filing Metadata
- Form type
- 4
- Filed
- Nov 30, 7:00 PM ET
- Accepted
- Dec 1, 7:07 PM ET
- Size
- 18.3 KB